Afuco™ Anti-Human HAMP ADCC Recombinant Antibody (LY2787106), ADCC Enhanced (CAT#: AFC-324CL)

Anti-HAMP ADCC Enhanced Antibody (LY2787106) is an ADCC enhanced antibody produced by our Afuco™ platform. This is a fully humanized antibody againsts hepcidin currently in phase I human trials for cancer-related anemia.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA

Figure 1 Percent change in hemoglobin level from baseline to end of cycle 4 (week 12).

Figure 1 Percent change in hemoglobin level from baseline to end of cycle 4 (week 12).

Values shown are for evaluable patients in study part B who received 10 mg/kg LY2787106 weekly (QW) without and with oral iron (cohorts B1 [n = 6] and B2 [n = 7], respectively). Only patients with a baseline and postbaseline result are included; for patients who did not reach week 12, their final assessment was used

Vadhan-Raj, S., Abonour, R., Goldman, J. W., Smith, D. A., Slapak, C. A., Ilaria, R. L., ... & Tuttle, J. L. (2017). A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia. Journal of hematology & oncology, 10(1), 73.

Figure 2 LY2787106 concentration-versus-time profile (a) and clearance-versus-dose scatter plot (b)

Figure 2 LY2787106 concentration-versus-time profile (a) and clearance-versus-dose scatter plot (b)

Vadhan-Raj, S., Abonour, R., Goldman, J. W., Smith, D. A., Slapak, C. A., Ilaria, R. L., ... & Tuttle, J. L. (2017). A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia. Journal of hematology & oncology, 10(1), 73.

Figure 3 Change in serum iron level (expressed as ratio relative to baseline) versus time course following (a) a single dose and (b) multiple weekly doses (after 5th dose).

Figure 3 Change in serum iron level (expressed as ratio relative to baseline) versus time course following (a) a single dose and (b) multiple weekly doses (after 5th dose).

Relative_Nominal_Time (h) is the protocol-scheduled time after last dose in hours presented on a log scale for greater clarity and better presentation of the earlier time point, where 168 h = 7 days = 1 week and 336 h = 14 days = 2 weeks. Data are displayed as mean ± SD

Vadhan-Raj, S., Abonour, R., Goldman, J. W., Smith, D. A., Slapak, C. A., Ilaria, R. L., ... & Tuttle, J. L. (2017). A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia. Journal of hematology & oncology, 10(1), 73.

Figure 4 Change in ferritin level (expressed as ratio relative to baseline) versus time course following (a) a single dose and (b) multiple weekly doses (after 5th dose).

Figure 4 Change in ferritin level (expressed as ratio relative to baseline) versus time course following (a) a single dose and (b) multiple weekly doses (after 5th dose).

Relative_Nominal_Time (hr) is the protocol-scheduled time after last dose in hours presented on a log scale for greater clarity and better presentation of the earlier time point, where 168 h = 7 days = 1 week and 336 h = 14 days = 2 weeks. Data are displayed as mean ± SD

Vadhan-Raj, S., Abonour, R., Goldman, J. W., Smith, D. A., Slapak, C. A., Ilaria, R. L., ... & Tuttle, J. L. (2017). A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia. Journal of hematology & oncology, 10(1), 73.

Figure 5 Transferrin saturation (percentage) concentration-versus-time profile following (a) a single dose and (b) multiple weekly doses (after 5th dose).

Figure 5 Transferrin saturation (percentage) concentration-versus-time profile following (a) a single dose and (b) multiple weekly doses (after 5th dose).

Relative_Nominal_Time (hr) is the protocol-scheduled time after last dose in hours presented on a log scale for greater clarity and better presentation of the earlier time point, where 168 h = 7 days = 1 week and 336 h = 14 days = 2 weeks. Data are displayed as mean ± SD

Vadhan-Raj, S., Abonour, R., Goldman, J. W., Smith, D. A., Slapak, C. A., Ilaria, R. L., ... & Tuttle, J. L. (2017). A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia. Journal of hematology & oncology, 10(1), 73.

Figure 6 Hepcidin (ng/mL) concentration-versus-time profile following (a) a single dose and (b) multiple weekly doses (after 5th dose).

Figure 6 Hepcidin (ng/mL) concentration-versus-time profile following (a) a single dose and (b) multiple weekly doses (after 5th dose).

Relative_Nominal_Time (hr) is the protocol-scheduled time after last dose in hours presented on a log scale for greater clarity and better presentation of the earlier time point, where 168 h = 7 days = 1 week and 336 h = 14 days = 2 weeks. Data are displayed as mean ± SD

Vadhan-Raj, S., Abonour, R., Goldman, J. W., Smith, D. A., Slapak, C. A., Ilaria, R. L., ... & Tuttle, J. L. (2017). A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia. Journal of hematology & oncology, 10(1), 73.


Specifications

  • Host Species
  • Humanized
  • Derivation
  • Humanized
  • Type
  • ADCC enhanced antibody
  • Species Reactivity
  • Human
  • Related Disease
  • Cancer

Product Property

  • Purity
  • >98% by SDS-PAGE and HPLC analysis
  • Storage
  • Store at -20°C. Open under aseptic conditions.

Target

  • Alternative Names
  • HAMP; hepcidin antimicrobial peptide; HEPC; PLTR; HFE2B; LEAP1; hepcidin; putative liver tumor regressor; liver-expressed antimicrobial peptide 1

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "HAMP"

Humanized Antibody

CAT Product Name Application Type
TAB-338CL Human Anti-HAMP Recombinant Antibody (TAB-338CL) ELISA Human IgG

Mouse Antibody

CAT Product Name Application Type
TAB-0306CL-S(P) Mouse Anti-HAMP Recombinant Antibody; scFv Fragment (TAB-0306CL-S(P)) ELISA, Neut, FC, Ferritin assay, FuncS Mouse scFv
TAB-0307CL-S(P) Mouse Anti-HAMP Recombinant Antibody; scFv Fragment (TAB-0307CL-S(P)) ELISA, Neut, FC, Ferritin assay, FuncS Mouse scFv
TAB-0308CL-S(P) Mouse Anti-HAMP Recombinant Antibody; scFv Fragment (TAB-0308CL-S(P)) ELISA, Neut, FC, Ferritin assay, FuncS Mouse scFv
TAB-0309CL-S(P) Mouse Anti-HAMP Recombinant Antibody; scFv Fragment (TAB-0309CL-S(P)) ELISA, Neut, FC, Ferritin assay, FuncS Mouse scFv
TAB-0306CL-F(E) Mouse Anti-HAMP Recombinant Antibody; Fab Fragment (TAB-0306CL-F(E)) ELISA, Neut, FC, Ferritin assay, FuncS Chimeric (mouse/human)

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for AFC-324CL. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare